News Hub | News Direct

Forum Health Launches Revolutionary PNOĒ Metabolic Device Transforming Weight Management, Fitness and Longevity

Forum Health

Forum Health, a premier provider of personalized integrative and functional medicine, announces the launch of the PNOĒ metabolic analysis device, offering precise insights into metabolic, heart, lung, and cellular health for personalized wellness. Now available in Forum Health’s Madison and Fond du Lac, Wisconsin clinics, the PNOĒ uses a data-driven approach to weight management, fitness, and longevity optimization. Schedule a PNOĒ assessment here: Fond du Lac or Madison. Julie Heyrman, MD: "We’re thrilled to bring this advanced technology to our patients in Wisconsin. The PNOĒ allows us to better tailor health solutions that address the root causes of weight gain, fatigue, aging, and cardiovascular risk." Through using only breath, the PNOĒ provides a comprehensive metabolic analysis on how effectively the body burns calories, the efficiency of the heart and lungs, and overall cellular performance. Patients receive personalized health plans tailored to their unique metabolic profile for improved wellness and disease prevention. Key Benefits of PNOĒ Metabolic Analysis: Precision Weight Management: Analyzes metabolism to optimize workouts, calorie intake, and macronutrient balance for sustainable weight management. Endurance Enhancement: Measures the efficiency of heart, lungs, and cells, identifying limiting factors and providing a customized plan to overcome them. Longevity Optimization: Calculates VO2 max, cellular health, and metabolic efficiency—key predictors of lifespan and well-being. Early Detection - Detects early risk factors for heart, lung, and metabolic conditions, empowering proactive health steps. Phil Hagerman, CEO: “Forum Health is committed to bringing the most advanced technologies to our patients, and the PNOĒ device represents a new frontier in personalized healthcare. By offering precise metabolic insights, we can create tailored health plans that drive better outcomes for the health issues most affecting our patient's overall well-being.” About PNOĒ PNOĒ is a state-of-the-art metabolic analysis device that provides comprehensive assessments of heart, lung, and cellular fitness through breath analysis. Learn more at pnoe.com. About Forum Health, LLC Forum Health, LLC is a nationwide provider of personalized healthcare steeped in the powerful principles of functional and integrative medicine. Our providers take a root-cause approach to care exploring lifestyle, environment, and genetics to help each patient achieve their ultimate health goals. Members have access to advanced medical treatments and technology, with care plans informed by data analytics and collaborative relationships. For more, visit www.forumhealth.com. Contact Details Britt Wittelsberger +1 410-852-0738 bwittelsberger@forumhealth.com Company Website https://forumhealth.com

October 01, 2024 08:50 AM Eastern Daylight Time

COLORESCIENCE® INTRODUCES TOTAL LASH™ MASCARA

Colorescience

Colorescience®, a leading dermatologist-recommended specialty skincare company, is launching Total Lash™ Mascara, an innovative, new all-in-one lash serum, conditioner and mascara that immediately enhances the appearance of lash length and volume for a vibrant, eye-opening effect. With every application, this clinically tested formula works to improve lash health with a blend of peptides and botanicals that nourishes the lashes while helping support the natural lash cycle for healthier, stronger, fuller and longer looking lashes. The Total Lash™ ingredient complex uses gentle, prostaglandin analogue-free ingredients and has been ophthalmology tested and confirmed to be safe for sensitive eyes and contact lens wearers. This formula is ideal for those who want to restore and improve their natural lashes, especially after discontinuing lash extensions, false lashes, or other lash procedures. Dr.Tanya Khan, Oculoplastic Surgeon and Board-Certified Ophthalmologist, led the clinical study. After a 12-week clinical trial with daily usage of Total Lash Mascara 90% of subjects reported their lashes looked longer. As measured by Dr. Khan, lashes were on average 24% longer compared to baseline. Over 92% of subjects reported less lash breakage and 94% reported lashes appeared fuller, thicker, and fluffier after twelve weeks of usage. Recalling these results, Dr. Khan shared, “During the clinical study, it became clear to me that patients were readily achieving their desired results of lash growth, density, thickness, and darkness when using the Total Lash™ product once per day. As an oculoplastic surgeon and ophthalmologist, I am even more amazed that the formula is well-tolerated by sensitive eyes and does not cause irritation or discoloration of the delicate skin around the eye area. I look forward to offering this product to my patients as a safe, effective, and gentle daily option that delivers lash enhancement without prostaglandins or extensions.” This multi-benefit formula enhances the appearance of length and volume, nourishes and strengthens the lashes and supports lash growth. Proven peptide Myristoyl Pentapeptide-17 stimulates the hair follicle to help support continued growth while botanical extracts optimize root health and help promote continued growth for longer, fuller looking lashes. The results are a visibly denser, more defined lash line and longer lashes that are hydrated and nourished. Panthenol and jojoba seed oil condition and nourish lashes to reduce breakage helping strengthen and prolong length and volume. Lastly, the formula immediately enhances lashes upon application while providing all-day smudge-free wear. This tubing mascara wraps each lash in a rich black iron oxide mineral pigment, making this dye-free formula ideal for sensitive eyes. Patricia Boland, VP of Research & Development at Colorescience says, “We created this formula with the tubing feature because our goal is always to treat and improve while delivering immediate enhancement and optimal wear. The skin around the eyes is especially thin and delicate, so extensive rubbing during removal of products can contribute to irritation. Instead, our Total Lash Mascara envelops each lash with our clinically proven treatment complex while maximizing wear-time, and the product removes effortlessly with warm water and a favorite cleanser.” ABOUT COLORESCIENCE Colorescience ®, the leading innovator in all-mineral sun protection, delivers transformational skincare solutions through wearable multifunctional products that provide immediate confidence and long-term visible results. Crafted for users who know that great results require daily skincare and protection, Colorescience ® uses cutting-edge technology and clinically tested formulas to ensure efficacy and provide reassurance to people of all ages, skin types, and concerns. Colorescience ® products speak for themselves through their wearability, published clinical studies, and skin-healthy ingredients. For more information please contact: Project MM, meredith@projectmmnyc.com Contact Details Meredith Winfrey meredith@projectmmnyc.com Company Website https://www.colorescience.com

October 01, 2024 08:00 AM Eastern Daylight Time

Men's Telehealth Company's Plans To Change Men's Wellness

Benzinga

By Johnny Rice, Benzinga Jacob Cohen, CEO of MangoRX (NASDAQ: MGRX), was recently a guest on Benzinga’s All-Access. MangoRX is focused on developing a variety of men's health and wellness products and services via a secure telemedicine platform. The company specializes in proprietary products and compounded medicines that elevate men’s ability to perform in all aspects of life. The company has several new products that it is in the process of developing and releasing in global markets from the U.S. to China. Learn more here: Featured photo by Brooke Cagle on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

September 26, 2024 08:30 AM Eastern Daylight Time

Video Image

Former USC Student-Athlete L Simpson Launches "Take No L’s" Collection with Shiekh at USC Village

Full Scope PR

Current USC student, former USC football player and fashion entrepreneur L Simpson is rewriting the playbook for student-athletes with the exclusive launch of his highly anticipated streetwear collection, “Take No L’s”, at Shiekh at USC Village on Sept. 26. What began as a middle school project has evolved into a brand that embodies a mindset of relentless determination: no losses, only lessons – whether it’s on the court, field or in life. “Take No L’s” gained significant traction throughout Simpson’s high school basketball career at Sierra Canyon High School (Chatsworth, Calif.), where he captained his team to back-to-back California Open State Championships alongside notable teammates Scottie Pippen Jr., KJ Martin, Cassius Stanley and Christian Koloko. The brand’s momentum continued to increase when he joined USC’s renowned football program. Coached by USC head coach Lincoln Riley alongside former teammates and current NFL players, Caleb Williams, Jordan Addison and Brenden Rice, “Take No L’s” quickly became a regularly worn brand among his teammates and coaches. “I’m thrilled for L,” said USC head coach Lincoln Riley. “It’s always great to watch our players achieve their dreams, both on and off of the field. Whether we’re on campus or around the city, our players and staff love wearing the brand. L is extremely bright and innovate, and I know he is going to be incredibly successful.” “This launch is special,” says Simpson. “I shopped at Shiekh as a kid. Whenever Jordans would drop or when I wanted new athletic gear, I would always ask my parents to take me to Shiekh. It truly does feel like a full- circle moment. We’re not just selling clothes; we’re promoting a mindset of going after your dreams and never accepting defeat. That’s what Take No L’s stands for—no losses, just lessons.” Take No L’s is a bold, confident and unapologetic premium streetwear brand featuring striking graphics and vibrant colors. The collection includes hoodies, cropped sweatshirts, t-shirts, sweatpants and hats, with prices ranging from $90 to $200. With significant attention from L’s influencer network, which boasts a combined reach of over 100 million followers, the brand is already generating buzz on social media. Join Simpson on Sept. 26 from 3 p.m. to 6 p.m. PT at Shiekh in USC Village for the official launch of the “Take No L’s” collection. Experience firsthand why “Take No L’s” is setting a new standard in streetwear. The event will include special appearances, exclusive products and live entertainment featuring stars like Storm Reid, Brenden Rice, Riri Simpson, Jazz Hill, Temi Ojoro, Tade Ojoro, Ceyair Wright, Amber Jasmine, Lboogz, and Saint Thomas. Don't miss this exciting celebration of fashion and culture! About L Simpson: L Simpson, current USC student and former student-athlete, is the founder of the “Take No L’s” brand. Inspired by sports, culture and the journey of perseverance, Simpson created “Take No L’s” to encourage people to live fearlessly and embrace a lifestyle without losses. Simpson’s collection combines bold design, high-quality fabrics and empowering messaging to create a distinctive streetwear line that resonates with today’s generation. L has previously hosted his own talk show on SLAM and recently co-hosted the “Almost Pro” podcast with former Heisman Trophy winner Caleb Williams. Simpson is currently pursuing a degree in communication from the USC Annenberg School of Communication and Journalism, and he will graduate in the spring of 2025. For more info on the brand, visit takenolsstore.com and follow Simpson on Instagram at @lboogz. About Shiekh Shoes: Style Elevated, Sneakers Celebrated. Shiekh offers a curated collection of footwear, apparel, and accessories. Explore top brands like Nike, Adidas, and Jordan at Shiekh. Shiekh stores can be found at premium locations in multiple states. For more information follow @Shiekh on Instagram and visit Shiekh.com Media Contact: Pia Malihi | Full Scope PR pia@fullscopepr.com # # # Contact Details Pia Malihi pia@fullscopepr.com Company Website https://takenolsstore.com/

September 26, 2024 01:12 AM Eastern Daylight Time

Image

Little Spoon Becomes The First and Only Baby Food Maker In the U.S. To Publicly Set EU-Aligned Safety Standards and Share Test Results for Heavy Metals, Pesticides + Plasticizers

Little Spoon

In a groundbreaking move for the baby food industry, Little Spoon, the largest online baby and kids food company in the United States, today becomes the first and only brand in the country to unveil its testing standards and results for heavy metals, pesticides and plasticizers, making a commitment to never sell any product that falls short of its strict limits. The launch of this significant transparency initiative comes in response to the ongoing national discussion about baby food safety, the urgent need for stricter industry standards, and staggering statistics from a recently commissioned study of 2,000 American parents with children under 2 years old. As national conversations on baby food safety rapidly gain steam, it has become impossible to ignore the concerning headlines on toxic levels of heavy metals, grocery store brand misinformation and deteriorating consumer trust. Little Spoon partnered with Talker Research to conduct a survey of 2,000 American Parents to pulse check the needs and standards of American parents, and the results uncovered astonishing levels of mistrust and concern around industry safety, federal regulations, and overarching brand commitment. In fact, 95% of parents agree that baby food brands should be doing more to address baby food safety concerns— and only 9% report a ‘high degree’ of trust in baby food companies. “Quality nutrition and confidence in the products that fuel your family are rights, not privileges.” said co-founder and CEO, Ben Lewis. “We view this as a fundamental responsibility for our industry and a key reason why Little Spoon exists in the first place. The standards for children’s food in the U.S. are maddeningly low. Parents deserve better, and we are doing our part to finally deliver what they deserve.” Established to bring change to a century old industry, Little Spoon is once again raising the bar in the category by testing and sharing results for every batch of baby food for 500+ contaminants including heavy metals, pesticides, glyphosate and plasticizers. With no current federal regulations set for limiting the levels of chemical contaminants in baby food in the U.S., Little Spoon has aligned its testing standards for heavy metals with the European Union (EU), a long-standing, trusted standard for safety and excellence in the baby space. Consumers can see exact testing limits for each contaminant through a dashboard viewable for every Babyblend product on the brand’s website and can confidently purchase products knowing Little Spoon will not sell any products that do not meet these standards. “This generation is plagued by concern regarding baby food safety — and for good reason.” said co-founder and Chief Product Officer of Little Spoon, Angela Vranich. “We have always crafted our products with the utmost care, using certified organic ingredients and differentiated processing. We knew we could meet the rigorous EU testing limits for heavy metals in our baby food, and it quickly became our obsession to provide the level of transparency parents truly deserve.” To draw further attention to this crucial issue for Little Spoon consumers and parents nationwide, the ‘Little Spoon, Big Change’ initiative will be driven by a comprehensive 360-degree marketing campaign launching today. Designed to meet parents’ growing demands for transparency and baby food safety, the campaign will feature media partners, celebrities, tastemakers, and experts including an expanded advisory panel which now features world-class experts in public policy and academics specializing in heavy metals. As a topic often fraught with fear mongering tactics, Little Spoon is leveraging experts, educators and a new AI-powered chatbot on their site to provide education for parents and support the wide-ranging questions that come with baby food safety. "We won't see large-scale changes until companies like Little Spoon take action," said Dr. Bruce Lanphear, an advisor to Little Spoon who studies childhood exposure to toxic chemicals. "Companies don't need to wait for regulations—they can lead the charge.” Test results for every Little Spoon Babyblend, alongside detailed ingredient sourcing information are now available on LittleSpoon.com, with plans to roll out additional transparency measures for their robust portfolio of products in the coming months. For complete details on the ‘Little Spoon, Big Change’ initiative including Little Spoon’s testing process, regulation limits, test results, and overall commitment to baby food safety, please visit LittleSpoon.com and follow @littlespoon on Instagram. Little Spoon is the leading direct-to-consumer kid’s food brand on a mission to make parents' lives easier, and kids healthier through high-quality, accessible feeding solutions from baby’s first bites through the big kid years. Little Spoon is conveniently delivering the future of kid’s food right to parent’s doorsteps with integrated products that age with your child through a portfolio of freshly-made baby food, early finger foods, toddler + big kid meals, and snacks that meet the modern standard on quality, nutrition and value. Since launch, the company has delivered more than 50 million meals, helping to simplify the lives of hundreds of thousands of parents across the U.S.. With more than 90% of new parents identifying as millennials, Little Spoon is here to disrupt the +$100B children's health and wellness market, offering modern solutions, trusted resources, and new ways to connect with a network of advisors and parents just like you. Learn more at LittleSpoon.com, or find Little Spoon on Instagram at @LittleSpoon. Contact Details Powers PR Alex Turk +1 516-306-2373 alext@powers-pr.com

September 25, 2024 09:03 AM Eastern Daylight Time

Image

AI Unpacks Generational Stereotypes, Highlighting Key Differences, but Beer Bridges the Gap

AIport

What happens when you ask generative AI models to depict Baby Boomers, Gen X, Millennials, and Gen Z? You might expect tech-challenged Boomers and avocado-loving Millennials. But what you get is far more interesting and in some cases, unexpected. A joint research project conducted by AIport and Turing Post last month analyzed over 1200 AI-generated images across four different models—Stable Diffusion, Midjourney, YandexART, and ERNIE-ViLG. The findings have revealed both familiar stereotypes and surprising quirks about how AI perceives these generations. Sad Boomers, Happy Zoomers? Contrary to the carefree Boomer stereotype, AI models like Midjourney depict Baby Boomers as introspective, or even somber, often bundled up and gazing wistfully into the distance—a reflection, perhaps, of their disillusionment with the unfulfilled ideals of the 1960s cultural revolution. However, the ERNIE-ViLG model, likely trained on datasets with a more collectivist cultural slant, shows 93% of Boomers smiling. This fascinating contrast underscores the cultural differences embedded in different AI models. Meanwhile, Gen Z’s images are vibrant and diverse, reflecting their reputation as a generation that embraces individuality, inclusivity, and self-expression. The AI-generated images depict Zoomers in colorful, highly detailed scenarios, making them the most visually distinct generation in the study. Generations Through the AI Lens The research explored how generations are portrayed in five key aspects of life: identity, relationships, work, lifestyle, and consumer habits. The AI models revealed consistent patterns and stereotypes; for example, males predominated in the depictions of Boomers and Gen Xers across all four models, while many images of Millennials and Zoomers showed greater diversity and more female representation. Surprisingly, Gen X appears to be the least well-understood generation by AI, characterized by fewer defining features compared to all other generations, likely due to the limited amount of training data available. The one stereotypical Gen X leitmotif that AI consistently identifies is their fondness for flannel shirts—an unmistakable symbol of the 1990s grunge scene worn by Gen Xers who were rebellious teenagers and young adults during that era. As for one (un)expected commonality… It’s beer. Whether they’re Millennials job-hopping or Boomers reminiscing about the good old days, AI consistently showed beer in 34% of the produced images across all generations. Prompt Engineering and AI Insights The prompts for this research were carefully crafted to avoid bias, using neutral phrases like "A Millennial at work" or "A Boomer relaxing." The results offer a telling look at how generative AI models mirror societal stereotypes, often shaped by the data they're trained on. These findings open the door to deeper discussions on how AI reflects, and sometimes distorts, cultural narratives. "Whether we think we can learn about generations from these images depends upon how confident we feel that the training data that went in is an accurate image of the self identity of a group,” explains Senior Engineer and Sociologist Stephanie Kirmer, who analyzed the findings. “For the younger sets, I don’t think we can know how much of it is media representation created by people outside the group versus how much is selfie-style personal expression. Some of what we’re getting, especially for the older groups who don’t contribute as much self-generated visual media online, is perceptions of that group from advertising and media, which we know has inherent flaws." About the Study The study examined the outputs of four globally recognized generative AI models, each with distinct aesthetic and cultural nuances, providing a comprehensive look at how each generation is portrayed visually. The selected models included Stable Diffusion, Midjourney, YandexART, and ERNIE-ViLG, offering diverse perspectives from different regions across the globe. Conclusion Whether confirming or contradicting societal stereotypes, AI-generated images provide a fascinating snapshot of how technology interprets generational differences. The fact that beer remains a unifying theme across all four models shows that, no matter our age, some things—like enjoying a cold one—transcend generational divides. To learn more about the project, visit https://www.aigenerations.tech/. Hero images for the media: Google Drive Link About AIport AIport is an emerging community of AI/ML enthusiasts and practitioners with a goal of providing a truly global view of the AI/ML/DS landscape. https://www.blog.aiport.tech/ About Turing Post Turing Post is everything you need to make smarter decisions about AI. https://www.turingpost.com/ Contact Details Nick Leighton nick.leighton@nettresultsllc.com Company Website https://www.aigenerations.tech/

September 23, 2024 10:00 AM Eastern Daylight Time

Industry Update: 3 Exciting Precision Oncology Players to Watch Following Summit’s Meteoric Rise: Silexion, Nuvectis, Scorpian

Global Markets News

Summit Therapeutics (NASDAQ: SMMT) recently captured headlines with the release of its Phase 3 data for ivonescimab, a targeted NSCLC therapy that has generated substantial buzz. The results from its trial conducted in China showed a dramatic 49% reduction in the risk of disease progression or death compared to Merck’s Keytruda, signaling a potentially disruptive force in NSCLC treatment. However, the news wasn’t without its concerns—since the trial data originates from China, there are questions about its applicability to broader, global populations. As noted by BMO Capital Markets’ Evan Seigerman: “Results may or may not be generalizable beyond the China-focused patient population initially assessed.” Despite this, Summit’s valuation has risen by over 100%, now approximating $19 billion. With such a high valuation, the company could see limited room for further significant gains, leading many in the industry to explore other emerging opportunities in precision oncology. Alongside Summit, there are quite a few other players in the field. Some if these companies have even already shown promising initial results and could see similar success in the future if they were to report positive results. These emerging players are worth watching for those interested in following precision oncology drug candidates and pipelines. Among them are precision oncology innovators such as Silexion Therapeutics, Nuvectis Pharma, and Scorpion Therapeutics, which we discuss below. Silexion Therapeutics: Disrupting the KRAS-Driven Cancer Space Silexion Therapeutics (NASDAQ: SLXN) is another under-the-radar player in the precision oncology space, with a focus on KRAS-driven cancers—a notoriously difficult target in oncology. While current small-molecule KRAS inhibitors are making progress, they are often limited to specific mutations, such as KRAS G12C, which accounts for a small percentage of cancers. Silexion’s RNA interference (RNAi) approach offers a broader solution, targeting a wider spectrum of KRAS mutations, particularly in pancreatic cancer, one of the deadliest and most treatment-resistant cancers. At the heart of Silexion’s approach is its LODER™ platform, which delivers siRNA directly to the tumor site, silencing KRAS mutations at the genetic level. This localized delivery not only increases efficacy by concentrating the treatment in the tumor, but it also reduces systemic side effects. Silexion’s next-generation candidate, SIL-204, is an optimized siRNA formulation designed to target pan-KRAS G12x mutations, positioning it to treat a broader range of KRAS-driven cancers beyond pancreatic cancer, such as lung and colorectal cancers. In Phase 2 trials for locally advanced pancreatic cancer, Silexion's LODER™ platform showed a 9.3-month improvement in overall survival when combined with standard chemotherapy. Additionally, the objective response rate (ORR) increased from 20% with chemotherapy alone to 55% with the combination, and in some cases, tumors that were initially non-resectable became operable after treatment with LODER™. These results are especially encouraging given the limited options available for pancreatic cancer patients. SIL-204, is expected to enter Phase 2/3 clinical trials in 2025-2026. What makes Silexion particularly intriguing is its current market valuation. Valued at aproximatly just ~$9 million following its SPAC merger, the company’s valuation could be perceived as low when compared to some of its peers, especially given its innovative technology and promising clinical achievements. Some have wondered whether this low valuation has more to do with dynamics post-SPAC companies. If Silexion can report positive results in its later-stage trials, the company’s outlook could dramatically improve, reflecting the potential of its RNAi-based platform. Like NXP900, SIL-204 could potentially have vast applications across multiple KRAS-driven cancer types, making Silexion a company to watch closely as it advances through clinical development. Nuvectis Pharma: Targeting NSCLC and Beyond by Inhibiting SRC/YES1 Kinases Nuvectis Pharma (NASDAQ: NVCT) has been quietly making strides in the precision oncology sector, developing innovative therapies aimed at overcoming treatment resistance in hard-to-treat cancers. Its lead candidate, NXP900, targets NSCLC by inhibiting the SRC/YES1 kinases, which play critical roles in cancer cell survival and resistance to current therapies. This approach positions NXP900 as a potential game-changer in the treatment of NSCLC, particularly in patients who have developed resistance to EGFR and ALK inhibitors, such as AstraZeneca’s Tagrisso and Novartis’ Alecensa. NXP900 is still in the early stages of clinical development, currently undergoing Phase 1 trials. However, preclinical studies have already shown that it has strong anti-tumor activity in resistant NSCLC models. Even more promising is its potential application beyond NSCLC. Like Summit's ivonescimab, NXP900 focuses on resistance, but it also has broader applications due to its ability to target multiple cancer types driven by SRC/YES1 pathways. This versatility makes it a promising asset not just for NSCLC but also for other difficult-to-treat cancers like squamous cell carcinomas. In addition to NXP900, Nuvectis is advancing NXP800, another precision oncology candidate that is further along in the clinical development process. NXP800 is currently in Phase 1b trials, targeting ARID1a-mutated cancers such as ovarian and endometrial cancers. The early clinical data for NXP800 is promising, showing positive responses in patients with platinum-resistant ovarian cancer. With two strong candidates in the pipeline, Nuvectis is positioning itself as a formidable player in the precision oncology landscape. As Summit’s ivonescimab continues to gain attention, Nuvectis’ earlier-stage NXP900, with its NSCLC focus and beyond, could see similar success in the future if clinical results continue to trend positively. Scorpion Therapeutics: Pioneering Mutant-Selective Therapies Scorpion Therapeutics is redefining the frontier of precision oncology with its focus on delivering highly selective small molecules targeting validated and previously undruggable cancer mutations. Its lead candidate, STX-478, is a mutant-selective, allosteric PI3Kα inhibitor currently in Phase 1/2 trials for advanced solid tumors. Early data presented at the ESMO Congress 2024 highlighted its potential, with STX-478 demonstrating a 23% overall response rate in breast cancer and a 21% response rate across all tumor types, positioning it as a potentially best-in-class PI3Kα inhibitor. STX-478 is notable for its ability to spare wild-type PI3Kα activity in normal tissues, avoiding the toxicities seen with previous PI3Kα inhibitors, such as hyperglycemia and rash. Tumor reductions were seen in 72% of patients treated with STX-478 as a monotherapy, with circulating tumor DNA levels dropping in 86% of patients. This mutant-selective precision could help overcome the limitations of existing PI3Kα inhibitors, which have struggled with dose-limiting toxicities. In July 2024, Scorpion raised $150 million in a Series C financing round, co-led by Frazier Life Sciences and Lightspeed Venture Partners. The additional funding will support the advancement of STX-478 and other pipeline assets, positioning Scorpion for further clinical success. Scorpion’s pipeline includes a broad range of wholly-owned compounds that target both validated and novel cancer targets, positioning the company for future expansion into larger patient populations. As STX-478 progresses through clinical development, Scorpion is poised to become a significant player in the precision oncology space, making it another company worth watching closely. Optimistic Outlook for Precision Oncology The precision oncology space is experiencing a golden era of innovation, with companies like Summit Therapeutics, Nuvectis Pharma, Silexion Therapeutics, and Scorpion Therapeutics leading the charge. As the focus shifts towards targeted therapies that address resistance mechanisms, the market is increasingly favoring companies with novel approaches and broad applications. Summit’s meteoric rise has shown that there is tremendous potential for companies that can demonstrate efficacy in overcoming cancer resistance. While Summit has already captured much of the current attention, companies like Nuvectis, Silexion, and Scorpion, with their earlier-stage pipelines, offer exciting opportunities for the industry to keep a close eye on. As these companies continue to report clinical data and advance through trials, the potential for breakthroughs in treating some of the most difficult cancers grows stronger. With targeted therapies offering the possibility of overcoming resistance without the need for chemotherapy, the future of cancer treatment looks brighter than ever. For those in the oncology space, keeping a close eye on emerging players like Nuvectis, Silexion, and Scorpion could lead to transformative developments as the field of precision oncology continues to evolve. * * * This update may include speculative forward looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. the BioTech and Pharma industries are volatile and risky and readers are advised to seek out preffesional advice in the relevent feilds from licensed profesionals. This update is for informational purposes only and is not intended to serve as financial, investment or any form of professional advice, recommendation or endorsement. Please review the full documentation detailing financial compensation disclosures and disclaimers the article is subject to. [ https://justpaste.it/ch2qt/pdf ]. Global Markets News Network is a commercial digital brand compensated to provide coverage of news and developments related to innovative companies as detailed in the full documentation and it is thus subject to conflicts of interest. Contact Details News Coverage ronald@futuremarketsresearch.com

September 19, 2024 07:45 AM Eastern Daylight Time

Mothers' Milk Bank California Welcomes New Board Members

The Mothers' Milk Bank

Mothers' Milk Bank California (MMBCA) today announced the appointment of three community leaders to its Board of Directors. These new members bring a diverse range of expertise and a shared passion for supporting vulnerable infants, further bolstering MMBCA's mission to provide life-saving donor human milk to those in need. Their leadership will play a critical role in advancing our efforts to ensure every baby has access to the vital nutrition they require. "Our new board members bring invaluable experience and a deep commitment to our mission. Their diverse backgrounds and shared dedication to supporting vulnerable infants will strengthen our efforts to provide life-saving donor human milk to those who need it most. We are excited to welcome them to the MMBCA family as we continue to work towards ensuring every baby has access to the vital nutrition they need,” Katie Anderson, Board Chair, Mothers' Milk Bank California Kristin is Senior Director of Development and Communications at the National Fragile X Foundation, a patient advocacy organization that supports families living with Fragile X, a group of conditions associated with alterations of the FMR1 gene on the X chromosome. She has over 20 years of experience in fundraising and non-profit management, event planning, and board and volunteer development. She earned a BA in Economics from UC Berkeley and a MA in Public Administration from the Middlebury Institute of International Studies. Peter Bailinson is a SF-based entrepreneur. He's worked at a variety of social impact organizations over his career, most recently as Director of Strategy and Business Operations at Atticus, a public interest law firm. Previously he was an Engagement Manager at McKinsey & Company and managed their global LGBTQ+ initiatives. He graduated with an MBA from Stanford University’s Graduate School of Business and a BA from Columbia University. He's passionate about making it easier for Americans to start and grow families and has conducted extensive research on human milk sharing. Lauren Morgan is a nonprofit professional currently in Program Operations at the Energy Foundation. She began her involvement with Mothers’ Milk Bank California as a donor, giving hundreds of ounces of breast milk. Passionate about scaling nonprofits, Lauren previously led fundraising at GRID Alternatives and managed youth programs at Planet Granite. She also served in AmeriCorps, developing a community garden program in Boston Public Schools. Lauren holds degrees in Religious Studies and Environmental Studies from Brown University and serves on the board of Weekend Adventures. For more information about Mothers' Milk Bank California and our new board members, please visit MothersMilk.org or contact Jennifer Benito at jbenito@MothersMilk.org About Mothers' Milk Bank California Founded 50 years ago, Mothers’ Milk Bank California is a leading nonprofit dedicated to providing screened, donated human milk to babies in need. As a founding member of the Human Milk Banking Association of North America (HMBANA), it helped set standards for nonprofit milk banks across North America. The organization collects, pasteurizes, and distributes safe human milk to hospitals and families, ensuring essential nutrition for infants. Committed to improving lives, Mothers’ Milk Bank California supports families and advances neonatal care. More information at MothersMilk.org ### Founded 50 years ago, Mothers' Milk Bank California is a leading nonprofit dedicated to providing screened, donated human milk to babies in need. As a founding member of the Human Milk Banking Association of North America (HMBANA), it helped set standards for nonprofit milk banks across North America. The organization collects, pasteurizes, and distributes safe human milk to hospitals and families, ensuring essential nutrition for infants. Committed to improving lives, Mothers' Milk Bank California supports families and advances neonatal care. Contact Details Jennifer Benito-Kowalski +1 408-831-7276 jbenito@mothersmilk.org Company Website https://camilkbank.org/

September 18, 2024 06:00 AM Eastern Daylight Time

Join Benchmark International's Exclusive Webinar "Seller Motivation: What Goes Into the Decision to Sell?"

Benchmark International

Are you considering selling your business? Deciding when and why to sell is one of the most significant decisions you’ll ever make as a business owner. While maximizing financial proceeds is often at the forefront of these decisions, it’s essential to recognize that it’s not the only factor. Life circumstances, time with family, and other qualitative considerations can often outweigh financial gain. To help you navigate this complex process, we invite you to join our upcoming webinar: Seller Motivation: What Goes Into The Decision To Sell? Space is filling up fast, so register today! Why You Should Register Selling a business is about more than just crunching the numbers. In this exclusive webinar, you’ll gain valuable insights into the full spectrum of motivations that drive business owners to sell. Understanding these motivations can help you make a well-rounded and informed decision about your business’s future. This webinar is a must-attend for business owners contemplating the sale of their business, particularly in today’s strong but disciplined market. By attending, you’ll be better equipped to evaluate both the financial and personal factors that play a crucial role in this life-changing decision. Whether you’re focused on securing a comfortable financial future or prioritizing time with loved ones, the information presented will help you weigh these considerations effectively. Spots are limited, so don’t miss this opportunity to secure your spot. What You’ll Learn This webinar offers actionable insights into the decision-making process for business owners. Here’s what you can expect to learn: The wide range of reasons why business owners choose to sell, beyond just financial incentives How personal life events, such as family needs and future aspirations, can influence your decision A look at the current M&A market and how buyers are approaching valuations How to balance personal and financial goals using the concept of indifference curves, which help weigh non-monetary values like time with family against financial returns By attending, you’ll gain the tools to make a decision that aligns with your long-term vision—both personally and financially. Spots Are Filling Fast – Register Now! If you’re ready to gain clarity on your motivations for selling and align your decision with both your personal and financial goals, this is the webinar for you. Don’t miss out—register now and take the first step toward making a well-informed, strategic decision about the future of your business. ABOUT BENCHMARK INTERNATIONAL: Benchmark International is a global M&A firm that provides business owners with creative, value-maximizing solutions for growing and exiting their businesses. Benchmark International has handled over $11 billion in transaction value across various industries from offices across the world. With decades of M&A experience, Benchmark International’s transaction teams have assisted business owners with achieving their objectives and ensuring the continued growth of their businesses. The firm has also been named the Investment Banking Firm of the Year by The M&A Advisor and the Global M&A Network as well as the #1 Sell-side Exclusive Privately-held M&A Advisor in the World by Pitchbook and Refinitiv's Global League Tables. Contact Details Brittney Zoeller +1 813-898-2350 zoeller@benchmarkintl.com Company Website https://www.benchmarkintl.com/

September 16, 2024 09:54 AM Eastern Daylight Time

Image